Elysium Health, the New York longevity company behind the NAD+ supplement Basis, has announced a move into peptides, saying it plans to offer six more peptides through its Elysium Health Rx service and has launched two research initiatives. The timing is not a coincidence: it follows an interim enforcement-discretion policy from the US Department of Health and Human Services.

Under that policy, HHS does not intend to take enforcement action against 503A compounding pharmacies, federal facilities or licensed physicians compounding with six peptide bulk substances, provided detailed safeguards are met. Those six are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.

What the policy does not do

It does not make any of the six FDA-approved, and it does not add them to the 503A bulks list. HHS can revisit the decision if safety signals or quality concerns emerge.

That distinction carries weight because regulators have treated BPC-157 as an unapproved drug that cannot legally be sold as a dietary supplement, and testing body BSCG says the same of TB-500. Compounding under enforcement discretion is not approval, and Elysium is routing the peptides through independent board-certified physicians rather than selling them as supplements.

A split verdict

FDA staff recommended against listing any of the seven peptides ahead of July's Pharmacy Compounding Advisory Committee meeting, citing weak characterization and limited safety and efficacy data. The committee backed six of them anyway, and some groups have since asked HHS to hold the policy.

HHS framed the move as a way to steer consumers away from research-use-only peptides from foreign manufacturers, and compounding groups welcomed it. Critics counter that the peptides have not yet been shown to be safe.

The research side

Elysium has launched the Peptide Evidence and Evaluation Resource, which will supply high-purity, characterized peptides to universities, hospitals, nonprofits and other qualified institutions through a traceable supply chain. A second project, TIME-PEP, will examine epigenetic changes linked to peptide use and any relationship to biological age.

The company says human clinical evidence for the six peptides is limited, which is a more honest line than most of this category manages. CEO Eric Marcotulli called unregulated suppliers and research-use-only products "a genuine public health challenge."

Why categorization matters

Google searches for peptides have risen roughly 200% in the past 12 months, according to Google Trends. The Council for Responsible Nutrition, the US supplement trade association, describes lawful supplements and grey-market peptides as "worlds apart."

Bottom line

A supplement company crossing into physician-prescribed compounded peptides is a notable repositioning, and the research arm suggests Elysium knows the evidence gap is its biggest exposure. Whether HHS leaves the policy in place is the unsettled part.